The Celerus Wave System is said to be the first and only solution to deliver precise, standardized histology and cytology results in 15 minutes. Intra-operative frozen tissue sections now undergo immunohistochemistry (IHC) staining regularly using the Wave System.
Dave Gross, newly named CEO of Celerus, said: “We’re delighted with the first closing of our series C financing. With this additional investment, we will further address market demand for rapid IHC testing and accelerate the commercialization of our onboard heating solution for the Celerus Wave.
“This allows for the decentralization of testing and moves results closer to the patient for faster decision making. By addressing the unmet needs of the anatomic pathology laboratory, the Celerus Wave provides real-time solutions for cancer patient management.”